QIAGEN N.V. Stock Forecast for 2023 - 2025 - 2030
Updated on 04/18/2024
QIAGEN N.V. Stock Forecast and Price Target
QIAGEN N.V. has an average price target of $50.00 recently offered by three notable experts for 2024, which would represent a potential upside of approximately 27.45% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of $61.86 and a low estimate of $42.50. Even if not interested in QGEN stock, you may want to be aware of its competitors.
27.45% Upside
QIAGEN N.V. Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, QIAGEN N.V.'s Price has decreased from $46.46 to $0.00 – a 100.00% drop. For next year, the 15 analysts predict Fair Value of $46.03, which would mean an increase of 100.00%. Over the next eight years, the pros' prediction is Fair Valueof $57.95, which would mean a eight-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AVGO Stock Forecast | Broadcom | Outperform |
8
|
$1.28k | Buy/Sell | $1.21k | 21.24% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$144.77 | Buy/Sell | $174.55 | 17.43% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.37 | Buy/Sell | $130.51 | 10.87% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$547.25 | Buy/Sell | $591.94 | 10.83% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF84.85 | Buy/Sell | CHF105.00 | 24.29% |
QIAGEN N.V. Revenue Forecast for 2023 - 2025 - 2030
In the last three years, QIAGEN N.V.'s Revenue has grown, increasing from $1.87B to $1.97B – an increase of 5.08%. For next year, the 18 analysts predict Revenue of $2.06B, which would mean an increase of 4.96%. Over the next eight years, the pros' prediction is Revenueof $3.29B, which would mean a eight-year growth forecast of 67.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF220.10 | Buy/Sell | CHF307.83 | 23.81% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$105.90 | Buy/Sell | $118.92 | 19.92% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$239.39 | Buy/Sell | $260.33 | 12.79% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GE Stock Forecast | General Electric | Outperform |
8
|
$155.67 | Buy/Sell | $144.00 | 8.24% |
| SIE Stock Forecast | Siemens | Outperform |
10
|
172.68€ | Buy/Sell | 178.14€ | 13.22% |
| 6758 Stock Forecast | Sony Group | Outperform |
6
|
¥12.67k | Buy/Sell | ¥16.23k | 27.12% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£15.90 | Buy/Sell | £17.30 | 22.64% |
| MRK Stock Forecast | Merck KGaA | Outperform |
18
|
147.20€ | Buy/Sell | 190.06€ | 24.32% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$232.21 | Buy/Sell | $284.47 | 20.58% |
QIAGEN N.V. EBITDA Forecast for 2023 - 2025 - 2030
QIAGEN N.V.'s EBITDA has decreased by 5.46% In the last three years, from $697.03M to $658.98M. For the next year, analysts are expecting EBITDA to reach $729.01M – an increase of 10.63%. Over the next seven years, experts predict that EBITDA will grow by 37.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SHL Stock Forecast | Siemens Healthineers | Buy |
8
|
52.08€ | Buy/Sell | 56.34€ | 15.21% |
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$134.55 | Buy/Sell | $138.82 | 12.60% |
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$118.29 | Buy/Sell | $159.28 | 27.72% |
QIAGEN N.V. EBIT Forecast for 2023 - 2025 - 2030
In the last three years, QIAGEN N.V.'s EBIT has decreased from $499.42M to $453.65M – a 9.16% drop! Next year, analysts are expecting EBIT to reach $569.16M – an increase of 25.46%. Over the next seven years, the forecast is for EBIT to grow by 139.30%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PHIA Stock Forecast | Koninklijke Philips N.V. | Hold |
18
|
18.94€ | Buy/Sell | 19.42€ | 2.96% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$74.92 | Buy/Sell | $81.06 | 12.12% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$199.97 | Buy/Sell | $241.28 | 20.02% |
QIAGEN N.V. EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, QIAGEN N.V.'s EPS has decreased from $2.15 to $0.00 – a 100.00% drop. For next year, the 15 analysts predict EPS of $2.13, which would mean an increase of 100.00%. Over the next eight years, the pros' prediction is EPSof $2.68, which would mean a eight-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$126.98 | Buy/Sell | $141.17 | 11.51% |
| INF Stock Forecast | Informa | Outperform |
15
|
£7.87 | Buy/Sell | £8.86 | 20.71% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
100.10€ | Buy/Sell | 105.55€ | 11.89% |
.jpg)